Pilot phenotype and natural history study of hereditary neuropathies caused by mutations in the HSPB1 gene by Rossor, AM et al.
Pilot phenotype and natural history study of hereditary neuropathies caused
by mutations in the HSPB1 gene
Alexander M. Rossor a,*, Jasper M. Morrow a, James M. Polke b, Sinead M. Murphy c,d,
Henry Houlden a, INC-RDCRC, Matilde Laura a, Hadi Manji a, Julian Blake a,e, Mary M. Reilly a
a MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, WC1N
3BG, UK
b Department of Neurogenetics, The National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK
c Department of Neurology, Adelaide & Meath Hospitals Incorporating the National Children’s Hospital, Tallaght, Dublin, Ireland
d Academic Unit of Neurology, Trinity College Dublin, Ireland
e Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, UK
Received 21 May 2016; received in revised form 17 September 2016; accepted 2 October 2016
Abstract
Mutations inHSPB1 are one of the commonest causes of distal Hereditary Motor Neuropathy (dHMN).Transgenic mouse models of the disease have
identified HDAC6 inhibitors as promising treatments for the condition paving the way for human trials. A detailed phenotype and natural history study
ofHSPB1 neuropathy is therefore required in order to inform the duration and outcomemeasures of any future trials. Clinical and neurophysiological data
and lower limb muscle MRI were collected both prospectively and retrospectively from patients with mutations in HSPB1. The natural history was
assessed by recording the weighted Charcot–Marie–Tooth Examination Score (CMTES) at annual intervals in a subset of patients. 20 patients from 14
families were recruited into the study. The average age of onset was in the 4th decade. Patients presented with a length dependent neuropathy but with
early ankle plantar flexion weakness. Neurophysiology confirmed a motor neuropathy but also showed sensory nerve involvement in most patients. Cross
sectional muscle MRI revealed soleus and medial gastrocnemius fat infiltration as an early signature of mutantHSPB1 disease. In this study neither semi
quantitativemuscleMRI, the CMTES nor neurophysiologywere able to detect disease progression inHSPB1 neuropathy over 1 or 2 years. Further studies
are therefore required to identify a suitable biomarker before clinical trials in HSPB1 neuropathy can be undertaken.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
Charcot–Marie–Tooth disease (CMT) is the most common
genetic neuromuscular disease with a population prevalence of
1 in 2500. The distal hereditary motor (dHMN) and hereditary
sensory neuropathies refer to forms of CMT in which the
disease burden falls on either motor or sensory nerves respectively
[1]. CMT and related disorders are a common and genetically
heterogenous group of diseases for which more than 80 causative
genes have now been described [2]. Mutations in the small
heat shock protein,HSPB1, although very rare, are the commonest
cause of dHMN and have also been reported to cause CMT2
[3,4]. In this study we aimed to characterise the phenotype and
natural history of a large, single centre cohort of patients with
mutations in HSPB1.
HSPB1 is a member of the family of small heat shock
proteins. Heat shock proteins (HSPs) are molecular chaperones
that are classified according to their molecular weight. HSPs
were originally identified as proteins that were induced following
heat shock and prevented or reversed the misfolding of cellular
proteins [5]. Why mutations in such a ubiquitously expressed
protein should result in an isolated neuropathy is not clear.
Mutations in HSPB1 were first identified as a cause of
autosomal dominant dHMN and CMT2 in 2004 [6] following
which mutations have been described spanning all regions of
the protein [7]. Four mutant HSPB1 transgenic mouse models
of dHMN have now been developed [8–10] and in 2011,
d’Ydewalle et al. observed that treatment with a selective
HDAC6 inhibitor successfully reversed the clinical phenotype
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of both S135F and P182L transgenic mice [8]. Further studies
involving the use of HDAC 6 inhibitors in other models of
inherited and chemotherapy induced neuropathy have revealed
promising pilot results [11,12] paving the way for future
clinical trials in patients. Trials of novel therapies in rare
diseases, however, require data on the detailed phenotype and
natural history of the disease with which to inform appropriate
trial design. In this paper we summarise the clinical,
neurophysiological and radiological phenotype of a large,
single centre cohort of 20 patients from 14 families with
mutations in HSPB1 followed up over a range of 1–10 years by
the same investigator (MMR).
2. Methods
Patients were recruited from the inherited neuropathy clinic
at the National Hospital for Neurology and Neurosurgery,
London. This study was approved by The National Hospital for
Neurology and Neurosurgery (NHNN) Research Ethics
Committee/Central London REC 3 09/H0716/61.
The HSPB1 mutations were identified by either Sanger
sequencing, whole exome sequencing (WES) or the use of
CMT2 disease specific next generation sequencing panels.
2.1. Clinical assessment
Neurological history, examination, and nerve conduction
study were performed in all patients. In a subset of patients
(patients 1 (ii), 8, 11, 12, 13 (i), 13 (ii), 13 (iv), 14 (ii)), the
Rasch modified CMT examination score (hereto referred to as
the weighted CMTES) was measured prospectively [13]. As
nerve conduction studies were not always performed at the
same time as the clinical examination, only the weighted
CMTES rather than the Rasch modified CMTNSv2 was
calculated. Patients were evaluated annually when possible.
2.2. Lower limb muscle MRI
Six out of 20 patients were scanned at 3 Tesla (Siemens
TIM Trio, Erlangen, Germany) in a supine position with
surface array coils to receive the signal from the thighs and
calves of both limbs. Patients were scanned with a clinical
imaging protocol comprising T1 weighted axial imaging and
axial STIR imaging as previously described [14]. Muscle MRI
scans were assessed for normal and abnormal muscle bulk and
for normal and abnormal signal intensity within the different
muscle groups. All muscle MRI scans were assessed by an
independent observer (JM) and scored according to the 2002
Mercuri classification [15]; a six-point semi-quantitative scale
with 0 = normal muscle, 4 = muscle completely replaced by
fat. The following muscles were scored bilaterally: rectus
femoris, vastus intermedius, vastus lateralis, vastus medialis,
semimembranosus, semitendinosus, biceps femoris, adductor
magnus, gracilis and sartorius in the thigh; tibialis anterior,
peroneus longus, medial gastrocnemius, lateral gastrocnemius,
soleus and tibialis posterior in the calf. The mean Mercuri
scores for the calf and thigh were also calculated as an overall
measure of disease severity on MRI. Serial MRI scans were
obtained for two patients. JM assessed these blinded to the
chronological order of these two sets of MRI scans.
2.3. Statistical analysis
All statistical analyses were performed using Microsoft
Excel (paired t-test) and SPSS version 14.0 (Spearman’s rank
coefficient and Chi squared analysis).
3. Results
3.1. Mutation analysis
Sanger sequencing of HSPB1 identified two previously
unreported mutations, S135Y and P182A. The S135Y mutation
was identified in a sporadic Somalian patient and is likely to be
pathogenic as the S135F mutation (i.e. substitution of the same
amino acid) is the commonest published pathogenic mutation in
HSPB1 [6,7]. DNAwas not available from the patient’s siblings
or parents.
The P182Amutation is likely to be pathogenic as it was found
to segregate with the disease in all six familymembers for whom
DNA was available (five affected and one unaffected). In
addition, two different missense mutations at the same amino
acid (182) have previously been reported to cause dHMN [6,16].
The P182A mutation in family 14 was initially missed by
Sanger sequencing of the HSPB1 gene in two affected family
members and subsequently identified using whole exome
sequencing. The reason for this false negative result was
identified as being due to a 4-bp insertion in intron 2 on the
same allele as the P182A mutation (HSPB1 comprises 3 exons
with the P182A mutation residing in exon 3). The 4-bp
insertion (GGTG) occurs within a G/C rich region, 3xGGTG
repeat sequence, and is present on dbSNP (rs30617181). The
additional GGTG repeat prevented this allele from being
amplified in the original PCR causing the sequencing to appear
normal. Use of a proof reading polymerase confirmed the
P182A mutation identified using WES as well as insertion of
the GGTG intronic sequence.
3.2. Clinical presentation
The average age of onset of the disease was in the 4th decade
although this ranged from the second to the 6th decade (see
Table 1.) There was no clear genotype–phenotype correlation;
the age of onset was in the second decade for families with both
the S135Y and P182A mutations i.e. both within and outside of
the alpha crystallin domain (See Fig. 1). Within members of the
same family the age of onset was often similar.
Prominent ankle plantar flexion weakness was a common
clinical feature unlike most other forms of CMT (see Table 2).
Nevertheless, whilst in 8 out of 19 patients, ankle plantar
flexion was as-weak as ankle dorsiflexion, in 10 patients, ankle
dorsiflexion was weaker than ankle plantar flexion and in only
one patient was ankle plantarflexion weaker than dorsiflexion.
The pattern of lower limb weakness was symmetrical in the
majority (18/20) of patients. Proximal lower limb weakness was
present in 8 out of 20 patients although the neuropathy followed
a length dependent pattern in all patients. Reflexes were usually
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preserved, or even brisk with the exception of the ankle jerks
which were absent. Plantar responses were either mute or flexor.
No patients reported delayed walking (>15 months). Five of
out 20 patients had collapsed foot arches and no patient had pes
cavus. Scoliosis was observed in one patient but this was not
severe enough to warrant surgical treatment. No patient needed
corrective foot surgery. In five patients in whom information
was available the mean interval between diagnosis and the use
of ankle foot orthoses was 15 years. All patients remained
ambulant. One patient required the use of a walking stick 24
years after the onset of his symptoms and uses a wheelchair
intermittently.
3.3. Neurophysiology
Neurophysiological data were collected both retrospectively
and prospectively from study participants. Nerve conduction
studies and EMG were performed in all 20 patients included in
this study. Follow up studies were performed in 11 patients over
a range of 1–10 years. Electromyography demonstrated length
dependent changes of chronic denervation defined by large
polyphasic motor units of increased duration and a reduced
interference pattern in all patients in the study. Spontaneous
activity in the form of positive sharp waves and frequent
fibrillation potentials was present in six out of 20 patients.
There was no significant change in any of the parameters
over an average 1 year period (Median CMAP = −0.12 mV;
Ulnar CMAP = −0.238 mV; Peroneal CMAP = +0.092 mV; Radial
SAP = +1.36 μV; Median SAP = −0.90 μV). The largest change
was of the sural SNAP which on average deteriorated by −1.8 μV
per year. Sensory involvement defined as a reduction in the
lower limb sensory nerve action potentials was present in most
patients (15/20) and did not appear to show any correlation
with the genotype. Even within members of the same family,
the degree of sensory involvement was variable (see
supplementary Table S1).
3.4. Muscle MRI
Fat infiltration is a key feature of chronically denervated
muscle. This can be visualised using muscle MRI in which fat
has high signal intensity relative to healthy muscle on T1
weighted sequences. To date, there have been two published
reports of muscle MRI in families with mutations in HSPB1
Table 1
A summary of the patients included in the study, their mutation, age of onset
and country of origin.
Family No. affected Inheritance Mean age at
onset/year
Origin Mutation
1 2 AD 40 England Pro39Leu
2 1 Sporadic 30 England Gly84Arg
3 2 AD 55 England Gly84Arg
4 1 AR 40 Pakistan Leu99Met
5 1 Sporadic 20 Somalia Ser135Tyr
6 4 AD 20 Poland Ser135Phe
7 6 AD 15 Canada Ser135Phe
8 2 AD 30 Gujurat Arg140Gly
9 1 AD 40 Gujurat Arg140Gly
10 2 AD 30 Gujurat Arg140Gly
11 2 AD 44 Gujurat Arg140Gly
12 1 AD 40 India Arg140Gly
13 5 AD 30 England Gln175X
14 11 AD 13 Ireland Pro182Ala
Fig. 1. A schematic diagram of the HSPB1 protein indicating the mutations identified in this study relative to the hydrophobic N terminal WDFP and the conserved
alpha-crystallin domains.
Table 2
A summary of the baseline clinical characteristics of patients with mutations in
HSPB1.
Patient Age at
examination
ADF APF FDIO APB Proximal UL/
LL weakness
1 (i) 79 2/4- 4-/4 4/4 4/4 N/N
1 (ii) 69 0/0 1/0 3/3- 4/4 N/Y
2 46 5/5 5/5 5/5 5/5 N/N
3 68 2/2 3/3 5/5 5/5 N/N
4 41 2/2 1/1 N/A N/A N/Y
5 43 1/1 4/4 1/1 4-/4- N/Y
6 41 1/1 4/4 4/4 5/5 N/N
7 34 0/0 0/0 4/4 5/5 N/N
8 51 0/0 1/1 3/3 3/3 Y/Y
9 48 N/A N/A N/A N/A N/A
10 53 1/1 4/4- 3/3 4/4 N/N
11 46 0/0 0/0 3/4 4/4 N/Y
12 44 4/4 4/4 5/5 5/5 N/N
13 (i) 48 5/5 5/5 5/5 5/5 N/N
13 (ii) 43 5/5 5/5 5/5 5/5 N/N
13 (iii) 62 3/3 3/3 N/A N/A N/Y
13 (iv) 48 0/0 0/0 4/4 4/4 N/Y
14 (i) 61 0/0 1/1 2/2 3/4 N/Y
14 (ii) 25 3/4 4/4 3/4 4/4 N/N
14 (iii) 27 1/1 4-/4- 4-/3 4/4 N/N
Roman numerals in parenthesis refer to family members. Numbers are Medical
Research Council grades for power (right/left), NA = not available,
ADF = ankle dorsiflexion, APF = ankle plantar flexion, FDIO = first dorsal
interosseous, APB = abductor pollicis brevis, UL = upper limb, LL = lower
limb, Y = yes, N = no.
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[17,18]. Both reports describe fatty infiltration of the medial
gastrocnemius and soleus muscles. In this study, muscle MRI
was performed in eight individuals from six families with
mutations in HSPB1. A wide spectrum of fatty infiltration was
seen at the calf level, from minimal fatty streaking (Fig. 2A) to
near total fatty replacement of all lower leg muscles (Fig. 2D).
In those with intermediate levels of involvement, medial
gastrocnemius and soleus appeared more affected than the
anterior and lateral compartments (Fig. 2E, F and Fig. 3).
Significant correlation was seen between ankle dorsiflexion
strength and Mercuri grade (rho = −0.9, p < 0.0001), and ankle
plantarflexion strength and Mercuri grade (rho = −0.8,
p < 0.05). There was no correlation between the degree of fatty
infiltration as determined by the Mercuri scores of the calf and
thigh and the overall severity of the neuropathy as determined
by the CMTES (Calf, rho = 0.7, p = 0.1, n = 6/thigh, rho = 0.6,
p = 0.2, n = 6). In addition, there was no correlation between
the degree of fatty infiltration of the calf and thigh and the age
of examination of the patient (Calf, rho = 0.29, p = 0.76, n = 8/
thigh, rho = 0.30, p = 0.76, n = 8).
3.5. Prospective natural history data
Ten patients with mutations in HSPB1 were entered into a
natural history study. Eight patients underwent follow up at
one year, seven patients follow up at two years and four patients,
follow up at three years. There was no significant difference in
the weighted CMTES at one (p = 0.7), two (p = 0.64) and three
years (p = 0.2, paired t-test, see Table 3). It was not possible to
calculate the weighted CMTES retrospectively as old clinical
examinations did not include quantitative vibration testing. There
was no correlation between the age at time of examination and
either the CMTES (rho = 0.64, p = 0.91, n = 6) or weighted
CMTES (rho = 0.64, p = 0.91, n = 6).
Fig. 2. T1 weighted axial MRI images of the left lower limb muscles at mid-calf level in patients with mutations in HSPB1. Denervated muscle shows fat infiltration
(white). A = patient 2 (Mercuri score = 6), B = patient 7 (41), C = patient 8 (48), D = patient 11 (46), E = patient 12 (34), F = patient 13 (i) (22), G = patient 13 (ii)
(20), H = patient 13 (iv) (41), I = Healthy volunteer. Abbreviations: MG = Medial Head of Gastrocnemius, LG = Lateral Head of Gastrocnemius, S = Soleus,
TP = Tibialis Posterior, TA = Tibialis Anterior, EDL = Extensor Digitorum Longus, PL = Peroneus Longus.
Table 3
A summary of the natural history of patients with mutations in HSPB1 as
defined by the CMT examination score (CMTES), parenthesis = weighted
CMTES score.
Patient Year
0 1 2 3 4
1 (ii) 17 (21) 12 (17) 14 (19) 17 (23) 16 (22)
8 9 (13) 10 (15)
11 15 (18) 7 (9) 8 (11)
12 2 (3) 4 (7) 2 (3) 3 (5)
13 (i) 5 (6) 9 (13) 8 (12) 9 (13)
13 (ii) 0 0 0
13 (iv) 16 (20) 14 (17) 15 (18) 15 (19)
14 (ii) 9 (13) 8 (11) 9 (13)
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To determine whether semi quantitative assessment of calf
muscle MRI was sensitive enough to detect disease progression
over 1–2 years, muscle MRI was performed at yearly intervals
in two patients with dHMN, one with a R140Gmutation and the
other with a Q175X mutation. Direct visual inspection of the
serial MRI scans did not reveal a difference over a 1 or 2 year
period. Semi-quantitative assessment also revealed no change
over 1 or 2 years (see Fig. 4).
4. Discussion
In this study we have described the clinical phenotype of
the largest single centre cohort of patients with mutations in
HSPB1 and reported prospective clinical data for a subset of
patients followed up over four years. This study includes patients
with mutations in HSPB1 spanning all regions of the HSPB1
protein. Unlike the most common form of CMT, CMT1A,
patients with mutations in HSPB1 had a later age of onset
(average 40). Another common feature in our cohort was early
plantar as opposed to ankle dorsiflexion weakness which often
resulted in symptoms of poor balance. The reason for the early
involvement of the soleus and gastrocnemius muscles is unclear
but may give important clues to the pathogenesis of the disease.
The study includes detailed prospective and retrospective
neurophysiological data for all 20 patients included in the study
and in whom a large number underwent repeated investigation
over a 10 year follow up period. In the majority of cases the
neurophysiology was performed by the same physician (JB). In
6 out of 10 individuals with a recordable sural SAP and in
whom there was a follow up nerve conduction study, there was
a decline in the sural SAP. In 6 out of 10 individuals with only
baseline neurophysiology, the sural SAPs were reduced. This
implies that sensory nerves appear to be affected to some
degree in most patients with mutations in HSPB1.
Although this is the largest natural history study to date, the
number of patients followed up was small and as a result no
firm conclusions can be reached as to the efficacy of the CMTES,
muscle MRI and neurophysiology for detecting change in a
larger group of patients.
Qualitative muscle MRI of the lower limbs was performed
in eight patients with mutations spanning the entire length of
Fig. 3. Frequency of Mercuri grades in thigh and calf muscles of HSPB1 patients at baseline (n = 8). The y axis represents the percentage of patients with a particular
Mercuri score for each muscle. At the level of the thigh there is sparing of Rectus Femoris andAdductor Longus. At the level of the calf the soleus, medial and lateral
gastrocnemius and peroneus longus muscles are more severely affected. RF = Rectus Femoris, VL = Vastus Lateralis, VI = Vastus Intermedius, VM = Vastus
Medialis, BFLH = Biceps Femoris Long Head, BFSH = Biceps Femoris Short Head, ST = Semitendinosus, SM = Semimembranosus, AL = Adductor Longus,
AM = Adductor Magnus, Sa = Sartorius, G = Gracilis, MG = Medial Head of Gastrocnemius, LG = Lateral Head of Gastrocnemius, So = Soleus, TP = Tibialis
Posterior, TA = Tibialis Anterior, EHL = Extensor Hallucis Longus, PL = Peroneus Longus.
54 A.M. Rossor et al. /Neuromuscular Disorders 27 (2017) 50–56
HSPB1. The MRI findings correlated with the clinical phenotype
showing early signs of denervation in the gastrocnemius and
soleus muscles. Follow-up lower limb MRI was obtained in
only two patients and was unable to detect change over a 1 or 2
year period using the semi-quantitative Mercuri score. This is
perhaps unsurprising as the Mercuri score was intended for
pattern description as opposed to longitudinal analysis. It was
noted that significant fat infiltration may be seen in muscles
with normal bedside strength assessment (e.g. Fig. 2F and G;
subjects with normal ankle strength) suggesting MRI may be
more sensitive to early disease than clinical assessment.
The development of transgenic mouse models of mutant
HSPB1 neuropathy and the encouraging preclinical studies of
HDAC6 inhibitors in HSPB1 and GARS neuropathy have
highlighted the need for robust natural history with which to
guide future trial design. Unfortunately, our study has failed to
show that semi quantitative muscle MRI, the CMTES or
neurophysiology are able to detect disease progression in
HSPB1 neuropathy. Further studies are therefore required to
identify a suitable biomarker before clinical trials in HSPB1
neuropathy are undertaken. HSPB1 related neuropathies,
however, are rare and any future prospective trial will require
patients to be recruited from multiple centres in order for
statistically significant changes in clinical and imaging
outcome measures to be identified.
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